NewcelX Employees

As of December 31, 2025, NewcelX had 12 total employees, including 9 full-time and 3 part-time employees. The number of employees decreased by 3 or -20.00% compared to the previous year.

Employees

Change (1Y)

-3

Growth (1Y)

-20.00%

Revenue / Employee

n/a

Profits / Employee

-$691,667

Market Cap

19.60M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2025	12	-3	-20.00%
Dec 31, 2024	15	3	25.00%
Dec 31, 2023	12	-19	-61.29%
Dec 31, 2022	31	-1	-3.13%
Dec 31, 2020	32	-	-

Related Stocks

Company Name	Employees
Pluri	142
Longeveron	38
Palatin Technologies	29
Lipocine	14
Cellectar Biosciences	11
VYNE Therapeutics	10
Allarity Therapeutics	8
AEON Biopharma	8

Employee Rankings

NCEL News

12 days ago - NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform - GlobeNewsWire
4 weeks ago - NewcelX submits NCEL-101 pre-investigational new drug briefing package to FDA - TheFly
4 weeks ago - NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes - GlobeNewsWire
6 weeks ago - NewcelX files to sell 2.26M common shares for holders - TheFly
2 months ago - NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - GlobeNewsWire
2 months ago - NewcelX announces release of updated presentation on Type 1 Diabetes program - TheFly
2 months ago - NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - GlobeNewsWire
3 months ago - NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing - GlobeNewsWire

More News